

BIO-TECHNE Corp  
Form 4  
August 22, 2016

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
*See Instruction*  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

**OMB APPROVAL**

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Bazan J. Fernando

(Last) (First) (Middle)

614 MCKINLEY PLACE N.E.

(Street)

MINNEAPOLIS, MN 55413

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol

BIO-TECHNE Corp [TECH]

3. Date of Earliest Transaction  
(Month/Day/Year)

08/18/2016

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_ 10% Owner  
☒ Officer (give title below) \_\_\_\_ Other (specify  
below) below)

Chief Technical Officer

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(D)	Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form  
displays a currently valid OMB control  
number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code	5. Number of Derivative Securities	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
---------------------------------------	------------------------------	-----------------------------------------	-----------------------------------------	------------------------	------------------------------------------	----------------------------------------------------------------	---------------------------------------------------------------------

Edgar Filing: BIO-TECHNE Corp - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)	(Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)							
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 76.02						<u>(1)</u>	07/31/2020	Common Stock	10,000	
Stock Option (Right to Buy)	\$ 76.02						<u>(2)</u>	07/31/2020	Common Stock	15,000	
Stock Option (Right to Buy)	\$ 94.35						<u>(3)</u>	08/12/2021	Common Stock	15,000	
Stock Option (Right to Buy)	\$ 108.49						<u>(4)</u>	08/07/2022	Common Stock	10,000	
Stock Options (Right to Buy)	\$ 108.49						<u>(6)</u>	08/07/2022	Common Stock	7,500	
Restricted Stock Units	<u>(5)</u>						<u>(6)</u>	<u>(6)</u>	Common Stock	1,200	
Stock Option (Right to Buy)	\$ 106.59	08/18/2016	A		14,476		<u>(7)</u>	08/18/2023	Common Stock	14,476	
Stock Option (Right to Buy)	\$ 106.59	08/18/2016	A		10,857		<u>(8)</u>	08/18/2023	Common Stock	10,857	
Restricted Stock Units	<u>(5)</u>	08/18/2016	A		1,759		<u>(8)</u>	<u>(8)</u>	Common Stock	1,759	

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Bazan J. Fernando 614 MCKINLEY PLACE N.E. MINNEAPOLIS, MN 55413			Chief Technical Officer	

## Signatures

/s/ Elizabeth M. Dunshee as Attorney-in-Fact for J. Fernando Bazan pursuant to Power of Attorney previously filed.

08/22/2016

\_\_\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Vests 3,333 shares on each of 8/1/14 and 8/1/15 and 3,334 shares on 8/1/16.

(2) Vests 3,750 shares on each of 8/1/14, 8/1/15, 8/1/16 and 8/1/17.

(3) Vests 3,750 shares on each of 8/12/15, 8/12/16, 8/12/17 and 8/12/18.

(4) Vests 2,500 shares on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.

(5) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

(6) Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(7) Vests 3,619 shares on each of 8/18/17, 8/18/18, 8/18/19 and 8/18/20.

(8) Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.